Lipid-lowering agents for nephrotic syndrome (Q24201863)

1

0 references

Hao Yuan

2

0 references

Junming Fan

3

0 references

Zi Li

4

0 references

Lanhui Jiang

Cochrane Database of Systematic Reviews

6

0 references

publication date

10 December 2013

0 references

published in

0 references

cites work

Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidemia: a preliminary report.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Treatment of nephrotic hyperlipoproteinemia with gemfibrozil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

21 January 2018

Lipids and the kidney

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Lipid-lowering agents for nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

Inefficacy of pefloxacin in steroid-responsive nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

7 January 2021

The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidemia in response to antiproteinuric treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

7 January 2021

Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

7 January 2021

The increased risk of coronary heart disease associated with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

7 January 2021

Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

7 January 2021

Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

7 January 2021

Progression of Lipoid Nephrosis to Renal Insufficiency

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

7 January 2021

Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

7 January 2021

Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

7 January 2021

Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005425.PUB2

7 January 2021